We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Lumosa

News List

Lumosa Therapeutics Announces Positive Results from Phase 2 Stroke Clinical Trial americanpharmaceuticalreview
August 04, 2021
Lumosa Therapeutics announced that its Phase 2a clinical trial of LT3001 successfully met its primary safety endpoint.
LT1001 (Naldebain(R)), an Extended-Release Analgesic Injection, Received Its Second Approval from Singapore's HSA prnasia
December 23, 2020
Lumosa Therapeutics is pleased to announce the market approval of LT1001 (Naldebain®), an extended-release analgesic injection, from Singapore's Health Science Agency (HSA). HSA is regarded as one of the regulatory reference countries in the world.
Lumosa to Initiate Phase 2 Human Clinical Trial for LT3001 to treat Acute Ischemic Stroke biospectrumasia
June 16, 2019
Enrolment process to accelerate in the US and Taiwan, China for Safety, tolerability and pharmacokinetic exploration of the novel drug